RU2195297C2 - Method for treating dystrophic diseases of eyes - Google Patents

Abstract

FIELD: medicine, ophthalmology. SUBSTANCE: method deals with treating dystrophic diseases of retina and an optic nerve. Firstly, one should resect conjunctiva and Tenon's membrane to form a pouch in Tenon's space, then a purse-string suture is applied and a peptide bioregulator is introduced into Tenon's space at 1000-10000 Da molecular weight isolated out of retina or bovine brain cortex, correspondingly, then a purse-string suture is tightened up. The method provides prolonged supply of preparation from Tenon's space into area of pathological process. EFFECT: higher efficiency of therapy. 2 cl, 6 dwg, 3 ex

Description

 The invention relates to medicine, in particular to ophthalmology, and can be used in medical practice for the treatment of patients with degenerative eye diseases.

In our country, according to the observations of G.P. Smolyakova [1], the incidence of involutional CHRD was 11.35 ⁺ 4.1 per 1,000 population.

 According to foreign authors, senile macular degeneration is the leading cause of blindness and low vision among the elderly in England, the USA, Germany and several other countries.

 Among the various forms of vascular pathology of the eye, central chorioretinal dystrophy occupies a rather significant place - 45.9% [2] and is observed in 29.6% of people over 50 [3].

 It should also be noted that in recent years this disease has become “younger” and has been diagnosed not only in the elderly, but also in middle age, which often leads to disability of the still able-bodied population [4]. In addition, the incidence of the disease is steadily increasing. According to the WHO (1986), an increase in patients with involutional CVD was detected.

 Dystrophic lesions of the optic nerve are also found in this age group and are often not an independent disease, but a consequence of various pathological processes that capture the visual pathway in various departments. In the vast majority of cases, central chorioretinal dystrophies are characterized by an extremely slow, often perennial course, in which it is difficult to distinguish between periods of remission and exacerbation. The tendency to terminate the process is rare. More often, dystrophy progresses steadily, gradually spreading in extent and in depth and more and more impaired vision, up to blindness. The finale of retinal dystrophies of various forms is optic atrophy, retinal detachment, moorings, atrophic foci, etc. This fact alone determines the important social significance of these clinical conditions [5].

 All of the above emphasizes the relevance of this problem in ophthalmology and determines the need to search for more effective methods of treating this eye pathology.

 Moreover, "numerous attempts to achieve an effect in the treatment of non-exudative form of involutional dystrophy with vasodilating, antikinin drugs (prodectin), vitamin therapy with rigorous analysis have not yielded positive results" [6].

 In the pathogenesis of many acquired chorioretinal dystrophies, hyalinosis is of particular importance, and in case of hereditary retinal dystrophies, metabolic disorders of nucleoproteins, chromoproteins, etc. are lost. Highly differentiated specialized retinal tissue is replaced in degenerative foci with newly formed connective or glial tissue.

 However, some lesions, for example, ethmoid lattice, cystoid dystrophy of the retina, its "thinning", are more often manifested by atrophy of the retinal tissue, as a result of which the "thinned" end-to-end defects of the affected areas remain unsubstituted, even undifferentiated, not to mention functioning tissue.

 According to modern concepts, the etiology and pathogenesis of central chorioretinal dystrophies are of great importance to metabolic, immunological, hormonal, genetic, enzymatic and other factors that gradually lead to a deterioration in the rheological properties of blood and microcirculation.

 The question of the treatment of involutional CCRD is also not completely resolved. Numerous works in search of new, more advanced treatment methods suggest that to date, ophthalmological science does not have a sufficiently effective treatment that could significantly increase visual fiction or prevent the progression of the process. Perhaps this is justified polyethylogy of the disease.

 Currently, conservative, laser and surgical treatment of dystrophic diseases of the retina and optic nerve is used. Conservative therapy is diverse, but ineffective and unstable.

 There is also a wide range of various kinds of drugs. These include lipotropic substances, angioprotectors, which improve the state of the vascular wall, agents that normalize microcirculation, including through platelet disaggregation.

 A distinct hypocholesterolemic effect is possessed, in particular, by atromide, clofibrate, and miskleron, which simultaneously increase the fibrinalytic activity of the blood and reduce the adhesion of platelets. The effectiveness of miskleron in atherosclerotic chorioretinopathies is confirmed by K.V. Trutneva et al. (1973), M.G. Margolis (1976) and others. A large role is played by angioprotectors that improve the state of the vascular wall. So parmedin (prodectin) prevents the deposition of cholesterol in the intima of the arteries, reducing platelet aggregation and normalizing the state of the endothelium, improves microcirculation. The rational appointment of vitamin E, B6. Biostimulants are prescribed, which, not being enzymes, affect the metabolic processes through enzymes. Under the influence of such drugs, a deep restructuring of the enzymatic system is carried out, which has an antihypoxic effect. The principles of tissue therapy are formulated by V.P. Filatov [7]. On the basis of the Odessa Institute of Eye Diseases and Tissue Therapy named after V.P. Filatov conducted a comprehensive and diverse study of the effects of tissue therapy under the guidance of EA Georgian and L.T. Kashintseva.

 Biogenic stimulants contribute to a faster absorption of retinal and preretinal hemorrhages, exudates on the fundus, and stabilization of the pathological process. In addition, under the influence of tissue therapy, there is a tendency to stabilize metabolic processes in the body, enhance reparative processes and improve the subjective state of patients. Tissue preparations favorably affect the immunological reactivity of the patient’s body, increasing the phagocytic function of blood leukocytes, enhancing cellular immunity, stimulating the B-system of lymphocytes. To obtain the most powerful effect, the combined use of PhiBS and placenta suspension is recommended.

 Tissue therapy almost does not cause allergization of the body, anaphylactic phenomena and does not give side effects. However, this therapy has a number of contraindications: acute infectious diseases, an acute period of inflammatory processes, severe damage to the liver and kidneys with impaired function of these organs, severe cardiovascular failure, high hypertension, acute gastrointestinal disorders, active forms of tuberculosis, pregnancy. It is also worth noting such a complication as the frequent occurrence of infiltration at the injection site of the placenta suspension, which requires special care when performing these manipulations, and they should be carried out only in a hospital setting.

 All these features do not allow the use of these drugs in all patients with degenerative diseases of the retina and optic nerve. Therefore, the most severe patients (hypertensive patients, tuberculosis patients suffering from acute inflammatory processes, etc.) who have a particularly high risk of the progression of the pathological process and the development of severe complications remain without pathogenetic therapy.

 The method of laser coagulation is recognized by all authors, but it is widely used and most effective only at the exudative, exudative-hemorrhagic and neovascular stage of CCRD.

 The use of low-energy laser radiation is advisable, however, according to some authors, its drawback is the short duration of the result and a decrease in efficiency with each subsequent course of treatment.

 Imperfect and surgical methods of treatment. Direct revascularization operations are difficult to perform technically and can be accompanied by severe intraocular complications, both during operations and in the postoperative period.

 Sympathetic denervation surgery is associated with circulatory disorders of the blood supply. Surgical methods aimed at improving blood supply to the ophthalmic artery by ligation of the main trunk of the external carotid artery or its branches or branches of the internal carotid artery, threaten severe complications for the general condition of the patient, up to the death from interventions on large vascular branches, are contraindicated in patients with central vascular diseases that patients with involutional CCRD often suffer from.

 The advantage of introducing drugs into the tenon space with pathology of the posterior part of the eye, in particular the retina, is known [8]. However, the introduction of drugs by the known method has some drawbacks: the difficulty of "getting" into the tenon space, since the introduction of drugs is "blind", without control, this can lead to trauma to the vessels, the formation of hemorrhage and hematomas; rapid resorption of drugs in the tenon space introduced by this method does not contribute to the achievement of high therapeutic efficacy of treatment.

 Known tool that restores the function of the retina of the eye (hereinafter - retinalamin) [9]. Retinalamine is a peptide bioregulator, which is a complex of polypeptides with a molecular weight of 1000-10000 D, obtained from the retina of calves by extraction with a 3% solution of acetic acid with the addition of zinc chloride and treatment of the supernatant with acetone [10].

 A known tool that normalizes the function of the brain (hereinafter - cortexin) [11]. Cortexin is a peptide bioregulator, which is a complex of polypeptides with a molecular weight of 1000-10000 D, isolated from the cerebral cortex. Cortexin is known for the treatment of dystrophic diseases of the optic nerve [12]. It should be noted that retinalamine and cortexin are approved for clinical use.

 To date, quite a lot of experience has been gained in the use of peptide bioregulators, both in clinical medicine in general and in ophthalmology in particular. In recent years, intramuscular and parabulbar administration of peptide bioregulators has been used in ophthalmology (retinalamine is administered parabulbarly daily at a dose of 10 mg, 10 injections per course; cortexin is administered intramuscularly daily at a dose of 10 mg, 10 injections per course) [9,12].

 The problem to which the invention is directed is to create a method for treating degenerative eye diseases that provides high therapeutic efficacy by introducing a peptide bioregulator with a molecular weight of 1000-10000 D into the "pocket" formed in the tenon space and then tightening the pocket with a purse string suture.

 A method of treating dystrophic eyes by administering a medicament consists in first making an incision in the conjunctiva and tenon shell, forming a “pocket” in the tenon space, then applying a purse string suture and introducing into the tenon space a peptide bioregulator with a molecular weight of 1000-10000 D, isolated from the retina of calves or the cortex of the calves, after which the purse string suture is tightened.

 In the treatment of dystrophic diseases of the retina, a peptide bioregulator isolated from the retina of calves (retinalamine) is used as a medicine, which is injected into the intershell space of the eye once in a dose of 10 mg of active substance.

 In the treatment of diseases of the optic nerve, a peptide bioregulator isolated from calf brain cortex (cortexin) is used as a medicine, which is injected into the inter-shell space of the eye once at a dose of 10 mg of the active substance.

 Clinical studies have shown that treating patients with degenerative eye disease by introducing a peptide bioregulator into a pocket formed in the tenon space, followed by tightening the pocket with a purse string suture, ensures a high therapeutic effect, which consists in increasing visual functions. The specified technique ensures accurate introduction of the bioregulator into the tenon space, which eliminates the risk of side effects and complications. In addition, the subsequent tightening of the "pocket" with a purse-string suture provides a prolonged flow of the bioregulator from the tenon space into the pathological process, which also provides a significant increase in visual functions.

 Thus, the introduction of a bioregulator in this sequence differs significantly from the intramuscular and parabulbar injections of the drug, as it significantly improves visual functions, which is confirmed by the results of treatment of patients with dystrophic diseases of the retina and optic nerve below.

 Clinical observations were performed on 65 patients (80 eyes) with central chorioretinol dystrophies of various origins. Among the patients there were 21 women and 44 men. All patients were diagnosed with central chorioretinal retinal dystrophy and optic atrophy at different stages of development. The age of patients is from 18 to 80 years. The duration of the disease ranged from 2 to 20 years. From the anamnesis, it is known that in 89.2% of cases (58 people), patients underwent traditional therapy repeatedly according to the general scheme (vasodilators, angioprotectors, anticoagulants and enzymatic preparations of thrombolytic action, vitamin therapy, biogenic stimulants, etc.), in other cases (10, 8%) patients did not receive treatment. Significant improvement in visual function and general condition was not achieved.

 All patients were examined according to methods generally accepted in ophthalmology. A special observation map has been created. The examination was carried out before administration, a week, a month, three and six months after the administration of the drug. Duration of observation from 1 to 6 months.

 The main evaluation criteria were such examination techniques as visometry, visometry without correction and with the best correction for near and far, visocontrastoperimetry, perimetry, assessment of dark and color adaptation, contrast-frequency fusion flicker method.

 For a more detailed determination of the severity of the pathological process, the nature of the pathogenetic changes and the evaluation of the effectiveness of the treatment, we used additional studies - the assessment of stereoscopic photographs, fluorescence fundus angiography, selective Doppler ultrasound. An examination of the fundus in patients with degenerative diseases of the retina and optic nerve using fluorescence angiography and ophthalmobiomicroscopy revealed such changes in retinal vessels that could not be detected using conventional direct or reverse ophthalmoscopy. In particular, it became possible to determine the degree of their permeability, to identify ischemic zones of the retina, and also to more accurately assess the dynamics of the process.

 Visual acuity was studied using Sivtsev-Golovin tables and a special table for the near. Visocontrastoperimetry was performed according to special tables [13,14]. Perimetry was carried out on a spheroperimeter.

 According to the invention, the treatment was carried out in the following way. After a general clinical and ophthalmologic examination, all patients underwent a skin scarification test for retinalamine and cortexin. After infiltration anesthesia with 2% solution of lidocaine, 2 ml of retrobulbar and topically 0.5% solution of dicain, an epibulbar dropwise incision of the conjunctiva is made in the upper-outer quadrant 8 mm from the limbus. The incision of the tenon capsule is 2 mm. A spatula forms a "pocket" in the tenon space into which a curved horse is introduced. A purse-string seam on a cut. 10 mg of the active substance is administered through the cannula once (the contents of the vial were dissolved in 0.5 ml of an isotonic sodium chloride solution). The purse string suture is tightened at the time the cannula is pulled out.

 In diseases of the retina, retinalamine, which is a lyophilized powder in 10.0 mg vials, was administered to patients.

 For diseases of the optic nerve, cortexin, which is a lyophilized powder in 10.0 mg vials, was injected into the intershell space of the eyes.

 In the postoperative period, subjectively, all patients noted improvement in well-being and emotional background, increased performance. None of the patients had allergic or side effects. On the second day after administration of the drug, visual acuity increased, dark and color adaptation improved. Increased visual acuity tended to increase.

 In the study, after a week, a significant positive dynamics was noted compared with the initial data: an increase in visual acuity by 0.01-0.4 (individually an increase in visual acuity from 0.1 to 1.0 with correction); expansion of visual fields by an average of 10-15 degrees. in standard meridians; an increase in the frequency-contrast sensitivity by 10-15% on average at all frequencies (an increase in the frequency-contrast sensitivity by 30-40% was individually noted). Inspection in a month by the same parameters: visual acuity increased (compared with the previous inspection) by 0.05-0.2; fields of vision expanded by another 5-10 degrees; frequency-contrast sensitivity at low and high frequencies increased by 10-20%. At the control examination after 3 and 6 months, the results of the treatment are stable. Only with a far advanced stage of central atherosclerotic chorioretinopathy in one patient (1 eye) and in one patient (1 eye) with terminal glaucoma, a positive effect was not objectively observed.

 Under the influence of retinalamin, as a rule, visual acuity was the first to change, cortexin - visual field. Already on the first day after surgery, patients noted subjective positive visual sensations, an improvement in dark and color adaptation. Increased visual acuity tended to increase in the postoperative period. The changes in visual acuity under the influence of peptide bioregulators in different age groups were uneven. Persons of a younger age, as well as those who have early stages of the disease, were more susceptible to treatment and gave a faster and more stable increase in visual acuity than older people with advanced stages of the disease.

 The following examples of clinical and experimental studies demonstrate the therapeutic efficacy of treating degenerative diseases of the retina and optic nerve.

Example 1
Patient G., 77 years old. Medical history 5529. More than 10 years have been observed for cataracts in both eyes. In 1992, extracapsular cataract extraction was performed on the left eye, and in 1995 on the right eye. Since 1995, initial arteriosclerotic chorioretinopathy has been identified. In 1998, she underwent a course of supporting trophic therapy, ophthalmic color correction according to the methodology of Professor T. P. Teterina. She noted an improvement in dark and color adaptation. Diagnosis: aphakia, initial atherosclerotic chorioretinopathy in both eyes. Before treatment by the claimed method: visual acuity of the right eye = hand movement in a person with a sphere + 13.0D = 0.1; visual acuity of the left eye = 0.02 with a sphere + 12.0D = 0.2. There are no lenses. IOP norm. On the fundus - the optic nerve disc with clear boundaries, a satisfactory diet, vascular sclerosis, small hemorrhages and whitish "dry" foci with clear contours along individual vessels. Frequency-contrast sensitivity is reduced in the right eye to 10% at all frequencies, in the left eye to 20%.

 After a general clinical and ophthalmological examination, the patient underwent a skin scarification test for retinalamine. After infiltration anesthesia with 2% solution of lidocaine, 2 ml of retrobulbar and topically 0.5% solution of dicain epibulbar droplet incision of the conjunctiva in the upper-outer quadrant 8 mm from the limbus. The incision of the tenon capsule is 2 mm. A “pocket” was formed with a spatula in the tenon space into which the curved horse was introduced. A purse-string seam on a cut. 10 mg of the active substance was injected through the cannula once (the contents of the vial with the active substance of retinalamin was dissolved in 0.5 ml of an isotonic sodium chloride solution). The purse string suture was tightened at the time the cannula was removed.

 In the postoperative period, there was a progressive increase in visual acuity in both eyes. When viewed after a month, the visual acuity of the right eye = 0.05 with a sphere of + 11.0D = 1.0. Visual acuity of the left eye = 0.05 with a sphere of + 11.0D = 1.0. IOP is the norm. Frequency-contrast sensitivity increased to normal at all frequencies in both eyes (see Fig. 1). Ophthalmoscopic picture - minor hemorrhages resolved. The rest of the picture is the same. Fields of view expanded by 20 degrees. (see figure 2).

 As a result of the treatment, the visual acuity of both eyes increased significantly, the fields of vision expanded, the frequency-contrast sensitivity indicators, as well as the dark and color adaptation, improved.

Example 2
Patient T., 73 years old. Case history 4306. More than 8 years has been observed with immature cataract, central chorioretinal dystrophy of the retina of both eyes. Periodically instilled 4% taufon, katachrome. Improvements in visual function is not noted.

 Diagnosis: immature nuclear cataract, central atherosclerotic chorioretinal dystrophy of both eyes, 2 tbsp. Before treatment by the claimed method: visual acuity of the right eye = hand movement in the face, color does not distinguish, the projection of light is uncertain; visual acuity of the left eye = 0.1 with a sphere of -1.0 D = 0.1 more clearly. Frequency-contrast sensitivity is not determined on the right, on the left at medium and low frequencies 10-15%. Due to low visual functions, the visual field cannot be obtained on the right, narrowed in the standard meridians by 15-30 degrees from the norm on the left. In the lenses, the initial clouding in the nuclear zone. The fundus with a wide pupil - optic nerve discs with clear boundaries of satisfactory nutrition, angiosclerosis, yellowish-white subretinal foci, small hemorrhages, redistribution of pigment. IOP is the norm.

 After a general clinical and ophthalmologic examination, the patient underwent a cutaneous scarification test for retinalamine. After infiltration anesthesia with 2% solution of lidocaine, 2 ml of retrobulbar and topically 0.5% solution of dicain epibulbar droplet incision of the conjunctiva in the upper-outer quadrant 8 mm from the limbus. The incision of the tenon capsule is 2 mm. A “pocket” was formed with a spatula in a tenon space into which a curved horse was introduced. A purse-string seam on a cut. 10 mg of the active substance was injected through the cannula once (the contents of the vial with the active substance of retinalamin was dissolved in 0.5 ml of an isotonic sodium chloride solution). The purse string suture was tightened at the time the cannula was removed.

 As a result of the treatment: on the first day after the operation, the patient noted an increase in dark and color adaptation, visual acuity of the right eye increased to the count of fingers in the face, began to distinguish between green and red colors. Visual acuity of the left eye unchanged.

 When viewed after a month, the visual acuity of the right eye = 0.05 does not correct, the visual acuity of the left eye = 0.2 with a sphere of -2.0D = 0.3. IOP is the norm. Ophthalmoscopic picture - minor hemorrhages resolved, the rest is the same condition. Frequency-contrast sensitivity: on the right it was possible to obtain at medium frequencies by 10%, on the left it increased at all frequencies by an average of 20% (see figure 3). Fields of vision: on the right, it was possible to obtain a residual field of vision, on the left it expanded on average by 5-10 degrees. (see figure 4). When viewed after 3-6 months, the treatment results are stable. As a result of the treatment, visual acuity, frequency-contrast sensitivity in both eyes increased, dark and color adaptation improved, and the field of vision expanded.

 Thus, the most effective way of treating degenerative diseases of the retina and optic nerve is the introduction of peptide bioregulators into the intershell space of the eye. The most pronounced effect is observed in patients of a younger age and with the initial stages of the disease. When using peptide bioregulators in patients with degenerative diseases of the retina and optic nerve, adverse reactions, complications and drug dependence were not detected even in individuals with an unfavorable allergic history. Peptide bioregulators are well tolerated by patients and are compatible with all known drugs.

Example 3
Patient I., 73 years old. The history of the disease is 6448. Since May 1998, it has been observed regarding partial atrophy of the optic nerve of the left eye. In history, in October 1998, he was injured in the left eye with a sliver while chopping wood. On October 27, 1998, an operation was performed on the left eye - removal of a dislocated lens, partial vitrectomy, implantation of the anterior chamber IOL + 19.0D (T-19). Since May 1998, post-traumatic partial atrophy of the optic nerve of the left eye was detected. In order to improve the functions of the optic nerve 05/20/99. 10 mg of a peptide bioregulator, cortexin, was introduced into the inter-shell space of the left eye.

 Diagnosis: partial atrophy of the optic nerve in the artifact left eye. Initial cataract of the right eye. Before treatment by the claimed method: visual acuity of the right eye = 1.0; visual acuity of the left eye = 0.5 not corr. In the anterior chamber, the IOL is located correctly. The iris is calm, with a purse string suture on the pupil edge. IOP norm. On the fundus - the optic disc with clear boundaries, decolorized. Angiosclerosis Frequency-contrast sensitivity is reduced in the left eye at high frequencies to 60%, at medium frequencies to 40%. The field of vision from the inside is limited to 5 degrees. Top, bottom and outside up to 30 degrees from the fixation point.

 After a general clinical and ophthalmological examination, the patient underwent a cutaneous scarification test for cortexin. After infiltration anesthesia with 2% solution of lidocaine, 2 ml of retrobulbar and topically 0.5% solution of dicain epibulbar droplet incision of the conjunctiva in the upper-outer quadrant 8 mm from the limbus. The incision of the tenon capsule is 2 mm. A “pocket” was formed with a spatula in a tenon space into which a curved horse was introduced. A purse-string seam on a cut. 10 mg of the active substance was injected through the cannula once (the contents of the vial with the active substance of cortexin was dissolved in 0.5 ml of isotonic sodium chloride solution). The purse string suture was tightened at the time the cannula was removed.

 In the postoperative period, there was a progressive increase in visual acuity in the left eye, an expansion of the field of view, and an improvement in the frequency-contrast sensitivity. When viewed after a month, visual acuity and condition of the right eye without negative dynamics. Visual acuity of the left eye = 1.0., IOP - the norm. Frequency-contrast sensitivity increased to normal at all frequencies (see figure 5). The ophthalmoscopic picture is the same. The field of view of the left eye expanded by 15-20 degrees (see Fig. 6). During examinations after 3 and after 6 months, no negative dynamics were detected. As a preventive measure re 28.12.99. 10 mg of cortexin was introduced into the inter-shell space of the left eye.

 As a result of the treatment, the visual acuity of the left eye significantly increased, the field of view expanded, the indicators of frequency-contrast sensitivity, dark and color adaptation improved.

 Thus, the authors first showed and substantiated in clinical practice that the method of treating dystrophic diseases of the eyes by introducing a peptide bioregulator with a molecular weight of 1000-10000 D into a pocket formed in the tenon space, followed by tightening the pocket with a purse string suture, allows not only to increase visual functions, but and normalize homeostasis.

 The treatment of degenerative eye diseases by introducing peptide bioregulators in this way restores homeostasis, influencing the pathogenetic mechanism of these diseases and, thus, eliminates the cause of the progression of degenerative eye diseases.

Sources of information
1. Smolyakova TP, Lysenko VS Pathogenetic approaches to the treatment of age-old PCB. Guidelines. - Khabarovsk, 1988.

 2. Shershevskaya O.I., Starkov G.L., Shershevskaya S.F. Aging eyes. - M., 1970.

 3. Therapeutic ophthalmology // Under. ed. M.L. Krasnova, N.B. Shulpina. - M., 1985.

 4. Katznelson L. A. Classification of atherosclerotic and hereditary dystrophies of the choriodea and retina. // West. ophthalmology. - 1973. - 6. - S.14-20.

 5. Ophthalmogeriatrics // Ed. Puchkovskoy N.A. - M .: Medicine, - 1982, - p.149-233.

 6. The use of tissue preparations in the complex treatment of patients with diabetes. - Method. recommendations // E.A. Gruzina, V.V. Lakiza, I.A. Perminov, L.T. Kashintseva - Odessa, 1981. - 22 p.

 7. Morozov V. G., Havinson V.X. A new class of biological regulators of multicellular systems - cytomedins // Successes in modern biology. 1983.V.96, issue 3 (6). from. 339-352.

 8. Morozov V.I. et al. Pharmacotherapy of eye diseases. M .: Medicine, 1989, p. 141.

 9. RF patent 2073518 "Means restoring the function of the retina of the eye", MKI A 61 K 38/00, 1993.

 10. Morozov V.G., Havinson V.Kh. Peptide bioregulators (25 years of experience in experimental and clinical studies). - St. Petersburg: Nauka, 1996 .-- 74 p.

 11. RF patent 2104702 "A method of obtaining from animal raw materials a complex of biologically active polypeptides that normalize brain function, pharmacological composition and its use", MKI A 61 K 38/00, 1996.

 12. Kuznik B.I. and other cytomedines. St. Petersburg: Nauka, 1998, p. 212-215.

 13. Volkov VV, Kolesnikova LN, Shelepin Yu.E. The technique of clinical visocontrastoperimetry // News. Ophthalmology. 1983, 3. 59 p.

 14. Shelepin Yu. E., Kolesnikova L.N., Levkovich Yu.I. Visocontrastoperimetry. L .: Nauka, 1985, 102s.

Claims (3)

 1. A method of treating degenerative eye diseases by administering a medicament, characterized in that the conjunctiva and tenon shell are first cut, a “pocket” is formed in the tenon space, then a purse string suture is applied and a peptide bioregulator with a molecular weight of 1000-10000 is introduced into the tenon space D, isolated from the retina or cortex of the calves, after which the purse string suture is tightened.  2. The method according to p. 1, characterized in that in the treatment of degenerative diseases of the retina as a medicine, a peptide bioregulator with a molecular weight of 1000-10000 D, isolated from the retina of calves, is used, which is injected into the tenon space of the eye once at a dose of 10 mg of active substance .  3. The method according to p. 1, characterized in that in the treatment of diseases of the optic nerve, a peptide bioregulator with a molecular weight of 1000-10000 D isolated from calf brain cortex, which is injected into the tenon space of the eye once at a dose of 10 mg, is used as a medicine active substance.

Images